Key result
Prophylactic carvedilol therapy in HER2-positive breast cancer patients receiving Herceptin significantly improved cardiac function parameters including LA volume index (P=0.012) and TAPSE (P=0.009).
Why the study?
Trastuzumab improves prognosis in HER2-positive breast cancer, but heart failure is a known complication.
Does prophylactic carvedilol therapy prevent systolic and diastolic dysfunction in HER2 positive breast cancer patients receiving Trastuzumab?
Cohort (n=65)
Does prophylactic carvedilol therapy prevent systolic and diastolic dysfunction in HER2 positive breast cancer patients receiving Trastuzumab?
Prophylactic carvedilol therapy significantly preserves echocardiographic parameters of systolic and diastolic function in HER2-positive breast cancer patients undergoing trastuzumab treatment over 3 months.
May support carvedilol prophylaxis during trastuzumab; leaves open confirmation by randomized trials.
Breast cancer is the most common cancer among the female population, and its prevalence is increasing worldwide. Trastuzumab (Herceptin) therapy improves prognosis in HER2 positive patients, but Heart Failure (HF) is one of its known complications. In this study, we aimed to assess the potential benefits of prophylactic carvedilol therapy in patients receiving Herceptin. Sixty five patients with HER2 positive breast cancer were enrolled in the study. All of the patients received Herceptin. Twenty seven patients also received carvedilol 6.25 mg twice daily, and 38 patients had usual care. Echocardiography was performed at baseline, and after three months in both groups and changes in cardiac function, parameters were compared between two groups. After 3 months, LA volume index (P=0.012), TAPSE (P=0.009), Tei index (P=0.015) and Lateral Longitudinal Strain (P=0.024) were significantly better in patients receiving carvedilol. Carvedilol can be effective in the prevention of systolic and diastolic dysfunction following Herceptin therapy.
No takes yet. Share an insight, caveat, or question.
Sherafati et al. (2019) conducted a cohort in HER2 positive breast cancer receiving Trastuzumab (n=65). Carvedilol vs. Usual care was evaluated on Changes in cardiac function parameters (LA volume index, TAPSE, Tei index, and Lateral Longitudinal Strain). Prophylactic carvedilol therapy in HER2-positive breast cancer patients receiving Herceptin significantly improved cardiac function parameters including LA volume index (P=0.012) and TAPSE (P=0.009).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: